Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1387 • ACR Convergence 2025
Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
Jeffrey Curtis¹, Emily Holladay², Antton Egana³, Anjana Lalla³, Yujie Su⁴, Fenglong Xie⁵, Amy Mudano⁴, Shanette Daigle⁴ and Sara McCoy⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²University of Alabama at Birmingham, Edmond, OK, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Wisconsin–Madison, Madison, WI
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disease characterized by systemic symptoms such as dryness, fatigue, musculoskeletal pain, and extraglandular manifestations. SjD may overlap…
Abstract Number: 1268 • ACR Convergence 2025
Development of the LupusCoach Chatbot: Results of a Focus Group
Leila Khalili¹, Pooja Desai², Maya Souvignier², Adrienne Pichon², Stephen Suh³, Alberto Nordmann-Gomes², Lena Mamykina² and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Columbia University Irving Medical Center, New York City, NY
Background/Purpose: Self-management education and coaching are successful interventions for managing chronic health conditions. However, accessibility of in-person coaching is limited; digital coaching is available and…
Abstract Number: 1070 • ACR Convergence 2025
Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
Mahnoor Javed¹, Deepak Jagannath², Alma Aveytia Camacho³, Alwyn Mathew³, Konrad Harms³, Soudabeh Daliri³ and Myriam Guevara⁴, ¹Houston Methodist, Richmond, TX, ²Houston Methodist Hospital, Sugar Land, TX, ³Houston Methodist, Houston, ⁴Houston Methodist, Houston, TX
Background/Purpose: Women with SLE are at an increased risk of developing cervical cancer, primarily by human papillomavirus (HPV) and immunosuppression. This elevated risk has been…
Abstract Number: 0945 • ACR Convergence 2025
Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization
Jorge Romo-Tena¹, Luz Blanco², Shuichiro Nakabo³, Victoria Hoffman⁴, Norio Hanata⁵, Mingzeng Zhang², Carmelo Carmona-Rivera⁵, Eduardo Patino-Martinez⁶, Dillon Claybaugh², Zu-Xi Yu² and Mariana Kaplan⁵, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²NIH, Bethesda, MD, ³NIAMS, NIH, Bethesda, MD, ⁴Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶NIH/NIAMS, Bethesda, MD
Background/Purpose: Nerve injury-induced protein-1 (Ninj1) is an adhesion molecule that plays various roles in immune and stromal cells, including the modulation of inflammation and a…
Abstract Number: 0905 • ACR Convergence 2025
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
Jinyang Li, Xiu Han, Yi Wang, Yiyi Li, Zhaoru Ma, Yang Li, Zhimin Zhang, Liu Li, Meng Ni, Jiangkun Bi, Xing Yang, Yao Xiong, Shuaixiang Zhou and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Immune reset, achieved through profound and sustained depletion of B cells and/or plasma cells, has demonstrated significant clinical efficacy in patients with severe and…
Abstract Number: 0649 • ACR Convergence 2025
Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Zhuoli Zhang¹, Shengyun Liu², Min Yang³, Yasong Li⁴, Qinghong Yu⁵, Xinwang Duan⁶, Qiang Shu⁷, Qibing Xie⁸, Yanfei Chen⁹, Daming Ou¹⁰, Lan He¹¹, Hongbin Li¹², Pingting Yang¹³, Juan Li¹⁴, Terry Yan¹⁵, Xin He¹⁶, Daniel Moldaver¹⁷, Ciara O'Shea¹⁸ and Liya Fan¹⁶, ¹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ³Nanfang Hospital Southern Medical University, Guangzhou, China (People's Republic), ⁴Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁵Zhujiang Hospital of Southern Medical University, Zhujiang, China (People's Republic), ⁶The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷Qilu Hospital of Shandong University, Jinan, China (People's Republic), ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic), ⁹The First Hospital of Lanzhou University, Lanzhou, China (People's Republic), ¹⁰The First Affiliated Hospital of University of South China, Hengyang, China (People's Republic), ¹¹The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic), ¹²The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ¹³The First Hospital of China Medical University, Shenyang, China (People's Republic), ¹⁴The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ¹⁵Medical Affairs, GSK, Shanghai, China (People's Republic), ¹⁶VEO, GSK, Shanghai, China (People's Republic), ¹⁷GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ¹⁸Global Medical Affairs, GSK, Dublin, Ireland
Background/Purpose: Belimumab, a B-cell modulator monoclonal antibody that selectively inhibits BLyS and reduces autoreactive B-cells that drive lupus disease activity, has consistently demonstrated improved efficacy…
Abstract Number: 0629 • ACR Convergence 2025
Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures
Pankti Mehta¹, Fadi Kharouf², Virginia Carrizo Abarza³, Qixuan Li⁴, Dafna D. Gladman⁵, Zahi Touma⁶ and Laura Whitall Garcia⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: We aimed to study the prevalence of subtypes of lupus arthritis and determine their association with clinical features, serology, and type I interferon signature.Methods:…
Abstract Number: 0612 • ACR Convergence 2025
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Fadi Kharouf¹, JuanPablo Diaz Martinez², Pankti Mehta³, Dafna D. Gladman⁴, Laura Whitall Garcia⁵ and Zahi Touma⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarials, particularly hydroxychloroquine, are a cornerstone of systemic lupus erythematosus (SLE) management, with well-established benefits including reduced disease activity, prevention of flares, and mitigation…
Abstract Number: 0596 • ACR Convergence 2025
Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
Diana Fernandez¹, Rosana Quintana², Karen Roberts³, Romina Nieto², Marina Scolnik⁴, Carmen Funes Soaje⁵, CINTIA OTADUY⁶, Veronica Saurit⁷, Valeria Arturi⁸, GUILLERMO ARIEL BERBOTTO⁹, Maria Constanza Bertolaccini¹⁰, Mario Eduardo Kerzberg¹¹, Maria de los Angeles Gargiulo¹², Cecilia Pisoni¹³, Ana Carolina Ralle¹⁴, Joaquín Martinez Serventi¹⁵, Ana Silva¹⁶, ODIRLEI MONTICIELO¹⁷, Henrique Mariz¹⁸, Laíssa Cristina Alves Alvino¹⁹, Eduardo Borba²⁰, Emily Figueiredo Neves Yuki²¹, Edgard Torres dos Reis-Neto²², Iris Guerra Herrera²³, Milena Mimica²⁴, Gustavo Aroca-Martínez²⁵, Antonio Iglesias-Gamarra²⁶, Carlos Alberto Cañas²⁷, Gerardo Quintana-Lopez²⁸, Carlos Toro-Gutierrez²⁹, Mario Moreno Alvarez³⁰, Olga-Lidia Vera-Lastra³¹, Margarita Portela Hernández³², Hilda Fragoso-Loyo³³, Luis H Silveira³⁴, Yelitza Gonzalez Bello³⁵, Carlos Abud-Mendoza³⁶, Jorge Antonio Esquivel Valerio³⁷, Marcelo Barrios³⁸, Lourdes Carolina Vázquez³⁹, Magaly Alva Linares⁴⁰, Manuel Ugarte-Gil⁴¹, Armando Calvo⁴², Roberto Muñoz-Louis⁴³, Ana Carina Pizzarossa⁴⁴, Gonzalo Silveira⁴⁵, Federico Zazzetti⁴⁶, Ashley Orillion⁴⁷, Urbano Sbarigia⁴⁸ and Guillermo Pons-Estel², ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ³Consultora externa de GLADEL, Rosario, Argentina, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁶Servicio de Reumatología Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ⁷Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁸Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, ⁹Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, ¹⁰Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, ¹¹Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, ¹²Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires; Buenos Aires, Argentina, Buenos Aires, Argentina, ¹³CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, ¹⁴Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁵Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁶Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, ¹⁷Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁸Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ¹⁹Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁰Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²¹Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ²²Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²³Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²⁴Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²⁵Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, ²⁶Universidad Nacional de Colombia, Barranquilla, Colombia, ²⁷Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁸Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²⁹Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ³⁰Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ³¹División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, Mexico City, Mexico, ³²Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³⁵Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, ³⁶Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, ³⁷Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁸Hospital de Clínicas II, Uruguay, Uruguay, Uruguay, ³⁹Facultad de Ciencias Médicas. Universidad Nacional de Asunción-Paraguay, Paraguay, Asunción, Paraguay, ⁴⁰HOSPITAL EDGARDO REBAGLIATI MARTINS, San Borja, Peru, ⁴¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁴²Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴³Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴⁴Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁵Facultad de Medicina - Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁶Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁸Johnson & Johnson, Beerse, Belgium

Background/Purpose: Previous studies have shown that male gender is an independent predictor of organ damage in patients with systemic lupus erythematosus (SLE), particularly in the…
Abstract Number: 0802 • ACR Convergence 2025
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Eric Morand¹, Victoria Werth², Richard Furie³, Sanjeev Roy⁴, Ruth Fernandez Ruiz⁵, Summer Goodson⁶, Hans Gühring⁷, Flavie Moreau⁶ and David Pearson⁸, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, ⁵EMD Serono, Billerica, PA, ⁶EMD Serono, Billerica, MA, ⁷The healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…
Abstract Number: 0218 • ACR Convergence 2025
Creating an EHR Lupus Outreach Workbench to Address Care Gaps
Ross Gilbert¹, Starla Blanks², Joy Buie³, Mary Cronin⁴, Jake Decker⁵, Laura Dickmann⁶, Cristina Drenkard⁷, Sancia Ferguson⁸, Shivani Garg⁹, David Gazeley⁵, Andrea Gilmore-Bykovskyi¹⁰, Gale Johnson¹¹, Patti Katz¹², Tristan Lazewski¹³, S. Sam Lim¹⁴, Jenna McGoldrick¹⁵, Katrina Phelps¹⁰, Edmond Ramly¹⁶, Rosalind Ramsey-Goldman¹⁷, Ann Rosenthal¹⁸, Dawn Thomas-Semanko¹⁹, Sarah Stoltz¹³, Patricia Tellez-giron²⁰, Amannda Weber²¹, Andrea Wipperfurth¹³ and Christie Bartels¹⁰, ¹Johns Hopkins University, Baltimore, MD, ²American College of Rheumatology, Atlanta, GA, ³Lupus Foundation of America, Washington, DC, ⁴retired, Fox Point, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Froedtert Health, Waukesha, WI, ⁷Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA, ⁸University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, ⁹University of Madison, School of Medicine and Public Health, Madison, WI, ¹⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹¹Wisconsin Department of Health Services, Madison, WI, ¹²UCSF, San Rafael, CA, ¹³UW Health, Madison, WI, ¹⁴Emory University School of Medicine, Atlanta, GA, ¹⁵SSM Health, Madison, WI, ¹⁶Indiana University - Bloomington, Bloomington, IN, ¹⁷Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Wisconsin, ¹⁹WI Chapter - LFA, Milwaukee, WI, ²⁰University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²¹University of Wisconsin (UW), UW Health, Madison, WI
Background/Purpose: Lupus affects up to 1.5 million people in the US with significant health disparities in care and outcomes that call for care delivery innovation.…
Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Benjamin Jones¹, Miles Smith², Rufei Lu², Carla Guthridge², Susan Macwana², Wade DeJager³, Nancy Olsen⁴, Catriona Wagner⁵, Judith James², David Karp⁶ and Joel Guthridge², ¹Oklahoma State University, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁶UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…
Abstract Number: 2696 • ACR Convergence 2025
Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
Eric Morand¹, Josefina Cortés-Hernández², Zahir AMOURA³, Julia Weinmann-Menke⁴, Britta Maurer⁵, Edouard Forcade⁶, Stephanie Finzel⁷, Jose Alvaro-Gracia⁸, Marc Scherlinger⁹, Alberta Hoi¹⁰, Yannick Muller¹¹, Rangi Kandane-Rathnayake¹², Ozana Fischer¹³, Beata Kovacs¹³, Frédérique Chaperon¹³, David Pearson¹³, Adrienne Lefeber¹⁴, Chih-Yung Sean Lee¹⁴, Jianping Yuan¹⁴, Vassilis Bitsikas¹³, Aditya Mahadevan Iyer¹⁵, Theodoulos Rodosthenous¹⁶, Melissa Fernandes¹³, Thomas Calzascia¹³, Richard Siegel¹³, Peter Gergely¹³ and Tamas Shisha¹³, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ³APHP, Paris, France, ⁴Department of Nephrology and Rheumatology and Center of Immunotherapy, Medical Center of the Johannes Gutenberg University, Mainz, Germany, ⁵Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ⁶CNRS-UMR ⁵¹⁶⁴ Immuno ConcEpT, Bordeaux University and Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, F-³³⁰⁰⁰, Bordeaux, France, ⁷Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁸Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, ⁹Department of Rheumatology, Hopitaux Universitaires de Strasbourg, Centre National de Référence RESO, Strasbourg, France, ¹⁰Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ¹¹Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, ¹²Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ¹³Novartis Biomedical Research, Basel, Switzerland, ¹⁴Novartis Biomedical Research, Cambridge, MA, ¹⁵Novartis Biomedical Research, Hyderabad, India, ¹⁶Novartis Pharmaceuticals UK Ltd, London, United Kingdom
Background/Purpose: Current evidence suggests that B cell depletion through CD19-directed chimeric antigen receptor T cell (CAR-T) therapies may offer promise in improving outcomes in severe…
Abstract Number: 2602 • ACR Convergence 2025
Cellular and molecular fine mapping in single-cell data pinpoints new immunopathology of systemic lupus erythematosus
Masahiro Nakano¹, Michihiro Kono¹, Kenichiro Asahara¹, Takayuki Katsuyama², Eri Katsuyama³, Takahiro Arakawa¹, Tsugumi Kawashima¹, Hajime Inokuchi¹, Takahiro Nishino¹, Haruka Takahashi¹, Bunki Natsumoto¹, Hiroaki Hatano¹, Yoshinori Matsumoto² and Kazuyoshi Ishigaki¹, ¹Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Yokohama, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with unknown etiology. While we previously identified key gene signatures of SLE using bulk RNA-seq…
Abstract Number: 2468 • ACR Convergence 2025
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Saira Sheikh¹, Vimal Derebail¹, Natalie Grovner¹, Gaurav Gulati², Mehrdad Abedi³, Meghan Sise⁴, Matthew Frigault⁴, Christopher Palma⁵, Patrick Reagan⁵, Cuoghi Edens⁶, Satya Kosuri⁶, Caitlin Elgarten⁷, Jon Burnham⁸, Jonathan Hogan⁹, Yvonne White⁹, Carl diCasoli⁹, Rebecca Estremera⁹, Jenell Volkov⁹, Daniel Nunez⁹, Fatemeh Hadi-Nezhad¹⁰, Thomas Furmanak⁹, Jason Stadanlick⁹, Larissa Ishikawa⁹, Zachary Vorndran⁹, Alexandra Ellis⁹, Jazmean Williams⁹, Steve Flanagan⁹, Quynh Lam¹⁰, Samik Basu⁹, Raj Tummala¹⁰ and David Chang⁹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of California, Davis School of Medicine, Davis, CA, ³University of California, Davis School of Medicine, Davis, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Rochester, Rochester, NY, ⁶University of Chicago, Chicago, IL, ⁷Children's Hospital of Philadelphia, Philadelphia, PA, ⁸Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁹Cabaletta Bio, Philadelphia, PA, ¹⁰Cabaletta Bio, Philadelphia
Background/Purpose: Current goals of treatment for systemic lupus erythematosus (SLE) are to achieve low disease state/remission, prevent flares, minimize organ damage, and decrease long-term morbidity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].